PeptideDB

NP213

CAS: 942577-31-3 F: C42H84N28O7 W: 1093.30

NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP21
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections[1][2].
Target IC50: fungal
Invitro NP213 (500-1000 μg/mL; 18 hours) increases the number of PI-stained T. rubrum NCPF0118 cells in samples. This results suggests that NP213 is fungicidal and the mechanisms of action involved membrane permeabilization[1].NP213 is against T. rubrum NCPF0118, shows different MIC values against T. rubrum NCPF0118, and the MICs varies depending on the source of the keratin. The MIC values are 16-32 mg/L, 125 mg/L, and 250 mg/L for NP213 in 1640 media containing human nail Keratin, human skin Keratin and Lamb’s wool Keratin, respectively[1].NP213 (2-3 hours; 0-8 μg/ml) has great activity against clinically relevant yeast, including candida spp, Cryptococcus spp and Trichosporon spp. For all 122 yeast isolates, with the median MIC100 values of 1-2 µg/ml[3].
In Vivo NP213 (25 mg/kg) is well tolerated in mice. In Murine models of acute disseminated candidiasis, NP213 is tolerated and efficacious and exhibits a half-life of approximately 4.5 h[3].
Name NP213
CAS 942577-31-3
Shortening Cyclo-RRRRRRR
Formula C42H84N28O7
Molar Mass 1093.30
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Mercer DK,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii [2]. Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.Probiotics Antimicrob Proteins. 2016 Jun;8(2):85-101. [3]. Novamycin®/NP339 Technology Summary